COMMUNIQUÉS West-GlobeNewswire

Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
03/02/2026
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable [...]
HFMA’s Vitalic Health to gather more than 50 payers, providers and tech leaders to address rising claim denials
03/02/2026
CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association’s Vitalic Health announced today it will convene more than 50 payers, providers and tech companies to simplify and standardize [...]
Department of Education Proposal Still Excludes Nursing from “Professional Degree” Definition
03/02/2026
ANA urges nurses, patients, and the public to submit comments demanding nursing be added SILVER SPRING, MD, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The American Nurses Association (ANA) is deeply concerned that the U.S. [...]
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
03/02/2026
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe -- ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non- [...]
SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility
03/02/2026
NORTH PALM BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced it has significantly reduced its short position across its cryptocurrency [...]
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03/02/2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its [...]
Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion
03/02/2026
ST VINCENT AND THE GRENADINES, Caribbean, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Eleusis , the world’s first legal luxury psychedelic immersion, using DMTx protocols, will officially debut in March 2026 on the island of [...]
Clever Care Health Plan Increases Enrollment by Nearly 50 Percent in 2026 Medicare Annual Enrollment Period
03/02/2026
Culturally competent Medicare Advantage plan also announces new grocery benefits at major retailers and community-centered grocery stores HUNTINGTON BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clever Care Health [...]
Mark Mikhael, CEO of Olympia and Wesley Pharmaceuticals, Appointed to the Florida Board of Pharmacy by Governor Ron DeSantis
03/02/2026
Healthcare veteran and compounding advocate to bring over 20 years of clinical excellence to the state’s regulatory body ORLANDO, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olympia and Wesley Pharmaceuticals, two of the [...]
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
03/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
MedRisk Acquires Horizon Casualty Services
03/02/2026
Strengthens MedRisk’s ability to deliver better outcomes and an elevated experience WEST CONSHOHOCKEN, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MedRisk, a leading provider of managed care solutions for the workers’ [...]
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
03/02/2026
Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a [...]
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
03/02/2026
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced [...]
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
03/02/2026
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s [...]
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
03/02/2026
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of [...]
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
03/02/2026
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE [...]
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
03/02/2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
03/02/2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat) in Fabry disease and [...]

Pages